In May 2014, Hanhui manufacturing site in Fuyang, Hangzhou city, Zhejiang Province, built with the investment of RMB 1.5 billion was put into operation with the scientific and technical personnel accounted for 13.5% of the total number of employees; there are 6 international advanced production lines including oral and lyophilized products; the site is equipped with the world advanced manufacturing equipment, designed and developed according to the industry 4.0 pursued by the industry; the intelligence-based design concept enables the high degree of man-machine interaction, ensuring the efficient operation of the production line; the factory facilities conform to the certification standards of US FDA and EU regulations, and implement the international advanced EHS concepts. The site passed China GMP certification and passed the US FDA audit for 4 consecutive years (2 of which with no defect).

Technology transfer of innovator drug, Minocycline Hydrochloride Capsules (Meiman), is approved for manufacturing, making Hanhui the first company in China to realize the localization of innovator drug.

Irbesartan Tablets, Rosuvastatin Calcium Tablets and Meropenem for Injection are the first three products in China passing the consistency evaluation; Minocycline hydrochloride capsules has been listed as Reference Listed Drug; and Hanhui is the first enterprise to pass the consistency evaluation of simvastatin tablets and fludarabine phosphate for injection.

Manufacturing technology transfer of Pfizer innovator Minocycline Hydrochloride Capsules (Meiman), Amlodipine Besylate and Atorvastatin Calcium Tablets (DuoDaYi), and Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin) have successfully completed to achieve the localization of high-quality innovator. Amlodipine Besylate and Atorvastatin Calcium Tablets (DuoDaYi) and Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin) have been included in the Approved Drug Catalog.

The manufacturing site strictly follows the quality management mode of “Stringent, Robust and Rigorous" and "Localization of innovator product, high-end equipment, systematization of manufacturing process and precision of information system”, closely follows the company’s development strategy, implements the company’s action plan, accelerates the company's development in informatization and dataization. A management mode of lean production and excellent operation is being developed based on the value flow analysis of the manufacturing process to realize the goals of lean manufacturing and smart factory.

In May 2014, Hanhui manufacturing site in Fuyang, Hangzhou city, Zhejiang Province, built with the investment of RMB 1.5 billion was put into operation with the scientific and technical personnel accounted for 13.5% of the total number of employees; there are 6 international advanced production lines including oral and lyophilized products; the site is equipped with the world advanced manufacturing equipment, designed and developed according to the industry 4.0 pursued by the industry; the intelligence-based design concept enables the high degree of man-machine interaction, ensuring the efficient operation of the production line; the factory facilities conform to the certification standards of US FDA and EU regulations, and implement the international advanced EHS concepts. The site passed China GMP certification and passed the US FDA audit for 4 consecutive years (2 of which with no defect).

The manufacturing site strictly follows the quality management mode of “Stringent, Robust and Rigorous" and "Localization of innovator product, high-end equipment, systematization of manufacturing process and precision of information system”, closely follows the company’s development strategy, implements the company’s action plan, accelerates the company's development in informatization and dataization. A management mode of lean production and excellent operation is being developed based on the value flow analysis of the manufacturing process to realize the goals of lean manufacturing and smart factory.

Technology transfer of innovator drug, Minocycline Hydrochloride Capsules (Meiman), is approved for manufacturing, making Hanhui the first company in China to realize the localization of innovator drug.

Irbesartan Tablets, Rosuvastatin Calcium Tablets and Meropenem for Injection are the first three products in China passing the consistency evaluation; Minocycline hydrochloride capsules has been listed as Reference Listed Drug; and Hanhui is the first enterprise to pass the consistency evaluation of simvastatin tablets and fludarabine phosphate for injection.

Manufacturing technology transfer of Pfizer innovator Minocycline Hydrochloride Capsules (Meiman), Amlodipine Besylate and Atorvastatin Calcium Tablets (DuoDaYi), and Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin) have successfully completed to achieve the localization of high-quality innovator. Amlodipine Besylate and Atorvastatin Calcium Tablets (DuoDaYi) and Piperacillin Sodium and Tazobactam Sodium for Injection (Tazocin) have been included in the Approved Drug Catalog.